

Emend® (aprepitant) – First-Time Generic

- On December 29, 2016, Sandoz launched an <u>AB-rated</u> generic version of Merck's <u>Emend (aprepitant)</u> capsules.
- Emend, in combination with other antiemetic agents, is indicated in patients 12 years of age and older and patients less than 12 years who weigh at least 30 kg for the prevention of:
 - Acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose <u>cisplatin</u>
 - Nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC)
- Emend capsules are also indicated in adults for the prevention of postoperative nausea and vomiting.
- Emend is also available as a brand <u>oral solution</u> and brand <u>powder for injection</u>. Refer to their respective drug labels for specific indication information.



optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

Rx News® is published by the OptumRx Clinical Services Department.

©2016 Optum, Inc. All rights reserved.